Featured Press Releases

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

ONFAB, High Potent Containment Provider, Expands into USA Market

ONFAB, High Potent Containment Provider, Expands into USA Market

  • 08 May 2024

ONFAB, a leading European provider of single-use, flexible containment solutions for the...

BARDA and Tiba Biotech Collaborate to Develop Next-Gen Influenza Therapeutics

BARDA and Tiba Biotech Collaborate to Develop Next-Gen Influenza Therapeutics

Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg/30 mL Multi-Dose Vials

Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg/30 mL Multi-Dose Vials

Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

Dr. Zivjena Vucetic Appointed as Chief Medical Officer at Mission Bio to Lead Biopharma Partnerships and Clinical Adoption

Dr. Zivjena Vucetic Appointed as Chief Medical Officer at Mission Bio to Lead Biopharma Partnerships and Clinical Adoption

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

  • P-Cure
  • 17 Feb 2026
To strengthen global AI, data strategy, evidence synthesis, and economic modelling capabilities, Precision AQ expands its senior leadership team

To strengthen global AI, data strategy, evidence synthesis, and economic modelling capabilities, Precision AQ expands its senior leadership team

  • Precision AQ
  • 17 Feb 2026
New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday

New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday

  • Celltrion
  • 16 Feb 2026
Breakthrough in Zika Virus Drug Discovery Reported by IRBM

Breakthrough in Zika Virus Drug Discovery Reported by IRBM

  • IRBM
  • 14 Feb 2026
A Breakthrough Study Confirms HYD LLC

A Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression.

  • HYD LLC
  • 13 Feb 2026
FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.